Published Paper Details:

For medications that are mostly absorbed in the upper gastrointestinal (GI) tract segments the stomach, duodenum, and jejunum floating drug delivery systems (FDDS) offer an extra benefit. The quantitative effectiveness of floating delivery systems in the fed and fasted states, the contribution of buoyancy to improving FDDS's gastro residence time (GRT), and the relationship between extended GRT and sustained release/pharmacokinetic features are some of the important, unresolved issues surrounding the logical development of FDDS. The polymers employed in floating drug delivery formulations and systems have advanced significantly, and they can now accomplish more than just prolong a drug's effective release period. It is detailed how polymeric excipients (Es) are referred to in the technology utilized to create floating drug delivery systems (FDDS). The most popular polymer groups, their characteristics, and their function in different technical techniques to attaining buoyancy have been identified based on the information provided in research articles. Furthermore, methods for altering the API release in these systems are explained, along with the Es that are employed. The present developments in the application of polymers in floating dosage form (FDF) technology are described, together with broad conclusions regarding the future of this field.